06.03.2013 Views

IMS Company Profiles - Report Buyer

IMS Company Profiles - Report Buyer

IMS Company Profiles - Report Buyer

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>IMS</strong> COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING<br />

De scrip tion: Dis trib u tor, pro moter. Prod uct<br />

ranges in clude: phar ma ceu ti cal products.<br />

NOVEXAL<br />

Full Name: NOVEXAL Ellas Ltd.<br />

Street Ad dress: Ag. Dimitrou 25, GR-174 55<br />

Alimos<br />

Tel: +30 10 9828 876<br />

Fax: +30 10 9827 211<br />

Email: novexal@otenet.gr<br />

De scrip tion: Es tab lished 2001.<br />

Con tacts (Pharm): Chair man: Thalia Koukidou;<br />

Gen eral Con tact: Thalia Koukidou<br />

Sub sid iary of: Sandoz, Ger many<br />

GUATEMALA<br />

NOVARTIS<br />

Full Name: Novartis Farmaceutica SA (ACC),<br />

Cen tral Amer ica & The Ca rib bean<br />

Postal Ad dress: Apartado Postal 1115, 01011<br />

Gua te mala City<br />

Street Ad dress: Anillo Periferico 30-31, Zona 11,<br />

01011 Gua te mala City<br />

Tel: +502 242-28-400<br />

Fax: +502 242-28-401<br />

De scrip tion: Im porter, dis trib u tor, pro moter,<br />

sales/detailer. Im ports, dis trib utes, pro motes,<br />

sells/de tails for other com pa nies. Prod uct ranges<br />

in clude: phar ma ceu ti cal prod ucts (branded, pre -<br />

scrip tion, non-pre scrip tion), oph thal mic prod ucts,<br />

vet er i nary pharmaceuticals. Es tab lished 1967.<br />

250 phar ma ceu ti cal em ploy ees in 2006. Di vi sions<br />

in clude: An i mal Health; Con sumer Health;<br />

Pharma; Oncology; Ophthalmics; Transplant.<br />

Rep re sen ta tives/De tail ers (Pharm, Num -<br />

ber): 101-500 (2006)<br />

Con tacts (Pharm): Chair man: Pi erre Werren;<br />

Com mer cial Op er a tions: Luis Roberto Torres;<br />

Mar ket Re search: Marco An to nio Mar ti nez; Gen -<br />

eral Con tact: Marco An to nio Martinez<br />

Phar ma ceu ti cal Sales: US$ 35-40 mil lion<br />

Prod ucts (% of Sales by Lead ing 5): 60-65%<br />

Ther a peu tic Classes (% of Sales by Lead ing<br />

5): 80-85%<br />

Dose Forms (% of Sales by Lead ing 5):<br />

95-100%<br />

Prin ci pal Prod ucts:<br />

CATAFLAM (antirheumatic non-steroidal)<br />

CO-DIOVAN (an gio ten sin-II an tag o nist com bi na -<br />

tion)<br />

DIOVAN (an gio ten sin-II an tag o nist plain)<br />

PANTECTA (antiulcerant)<br />

VOLTAREN (antirheumatic non-steroidal)<br />

Ther a peu tic Range:<br />

anti rheu ma tics sys temic 35%<br />

renin-an gio ten sin sys tem agents 27%<br />

ant ac ids/antiflatulents/antiulcerants 10%<br />

antiepileptics 7%<br />

antiasthma and COPD prod ucts 4%<br />

Lead ing Dose Forms:<br />

coated tab lets 50%<br />

tab lets 19%<br />

cap sules 12%<br />

liq uids 9%<br />

am poules 5%<br />

HONDURAS<br />

NOVARTIS CON SUMER HEALTH<br />

Street Ad dress: Colonia Alameda, Casa No<br />

1104, Tegu ci gal pa<br />

Tel: +504 232-7337<br />

Fax: +504 232-4886<br />

Phar ma ceu ti cal Sales: US$ 8-9 mil lion<br />

Prod ucts (% of Sales by Lead ing 5): 60-65%<br />

Ther a peu tic Classes (% of Sales by Lead ing<br />

5): 80-85%<br />

Dose Forms (% of Sales by Lead ing 5):<br />

80-85%<br />

Prin ci pal Prod ucts:<br />

ESPASMO CANULASE (di ges tive in clud ing en -<br />

zymes)<br />

VOLTAREN EMULGEL (antirheumatic top i cal)<br />

LAMISIL TOPIC (dermatological antifungal)<br />

MEBOCAINA WT (throat prep a ra tion)<br />

MEBOCAINA (throat prep a ra tion)<br />

Ther a peu tic Range:<br />

di ges tives in clud ing di ges tive en zymes 20%<br />

cough and cold prep a ra tions 18%<br />

anti rheu ma tics top i cal 16%<br />

throat prep a ra tions 15%<br />

dermatological antifungals 13%<br />

Lead ing Dose Forms:<br />

tab lets 26%<br />

gels/sols 18%<br />

spe cial solid forms 16%<br />

liq uids 14%<br />

creams 10%<br />

© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 174

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!